10 September 2015: Clinical Research
Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis
Yaosheng Liu ABEF , Haifeng Qing BDE , Xiuyun Su CD , Cheng Wang DE , Zhou Li BC , Shubin Liu ACDF
DOI: 10.12659/MSM.894357
Med Sci Monit 2015; 21:2694-2700
Abstract
BACKGROUND: Previous studies have reported CD44 expression played an important role in the development and progression of tumor. The aim of study was to investigate whether single nucleotide polymorphisms (SNPs) of CD44 gene were associated with risk of non-small cell lung cancer (NSCLC), survival and occurrence rate of bone metastasis in patients with NSCLC.
MATERIAL AND METHODS: A total of 234 patients with NSCLC between 2003 and 2010 were enrolled in this study and 468 healthy persons were used as controls. Two polymorphisms, rs13347 and rs187115, in the CD44 gene were genotyped using DNA from blood lymphocytes. For statistical analysis we used the chi-square test, Fisher’s exact test, Kaplan-Meier method, and log-rank test.
RESULTS: CD44 gene rs13347 polymorphism was not associated with NSCLC risk. For rs187115, the association with NSCLC risk was observed (P<0.001). Allele G carriers had significantly higher occurrence rates of bone metastasis (OR=0.4, 95%CI: 0.20–0.64, P<0.001) and more advanced tumor stage (OR=2.6, 95%CI: 1.50–4.45, P=0.001) compared to carriers of allele A. The survival rates for patients with AA genotype were significantly higher than for patients with the AG+GG genotypes (P<0.001). In multivariate analysis of survival in NSCLC patients, significant predictors were CD44 gene (AG+GG) (RR=0.48, 95%CI: 0.34–0.68, P<0.001), tumor stage (RR=0.45, 95%CI: 0. 0.31–0.65, P<0.001), and bone metastasis (RR=1.52, 95%CI: 1.05–2.21, P=0.027).
CONCLUSIONS: CD44 gene rs187115 polymorphism is a potential predictive marker of survival in NSCLC patients, and is significantly correlated with bone metastasis and tumor stage.
Keywords: Antigens, CD44 - genetics, Alleles, Bone Neoplasms - secondary, Carcinoma, Non-Small-Cell Lung - pathology, Genotype, Lung Neoplasms - pathology, Lymphocytes - cytology, Polymorphism, Single Nucleotide
Background
Lung cancer is the most common cause of cancer-related deaths worldwide, with more than 1.6 million new cancer cases and 1.4 million deaths in the year 2008 [1]. More than 80% of patients with primary lung cancer were pathologically diagnosed with non-small cell lung cancer (NSCLC) [2,3]. Approximately 55% of patients with NSCLC suffer from distant metastases [4], including to bone, liver, lung, and brain. Bone is the most common site for distant metastasis in NSCLC patients [5]. It has been reported that 30–65% of patients with NSCLC will develop bone metastases [6], with a median survival of less than 8 months [7,8]. Bone metastases can result in significant morbidity and severely decreased quality of life [9–11] due to various skeletal complications such as pathological fractures, serious bone pain, spinal cord compression, and hypercalcemia [6,12,13].
To date, the exact molecular and cellular mechanisms of the development of NSCLC and bone metastasis in NSCLC are still unclear. Many studies [14–17] have recently reported that genes, including osteopontin, CCR2-64I, XRCC1, and IL-1β gene, may play roles in the emergence and progression of NSCLC.
The CD44 gene, located on chromosome 11p13 [18], encodes a cell surface glycoprotein – CD44 [19–21]. As a cell-surface glycoprotein, CD44 is widely known as a cell-surface receptor for osteopontin and hyaluronate and it mediates cellular adhesion to the cell-extracellular matrix (ECM), which is correlated with tumor cell migration [22,23]. Besides its roles in many cellular processes, CD44 plays a crucial role in tumor cell differentiation, invasion, and metastasis [24,25]. Overexpression of CD44 reportedly leads to poor clinical outcomes and poor prognosis for human tumors [26–28]. Recent studies have shown that the CD44 gene interacts with proliferation, migration, and invasion of tumor cells [29,30], and that genetic variants of CD44 are associated with the survival, risk prediction, and prognosis of patient with NSCLC [22,26,31,32].
As the most common type of DNA sequence variation, single-nucleotide polymorphisms (SNPs), may affect the expression of certain genes [33,34]. Previous studies have reported that SNPs rs13347 and rs187115 in CD44 gene were significantly associated with the risk of human tumors [32,35–37]. However, few studies have investigated the association of CD44 polymorphisms with survival of NSCLC and risk of bone metastasis. Therefore, we conducted the present study to investigate whether the 2 SNPs (rs13347 and rs187115) in the CD44 gene have roles on the survival of patients with NSCLC and to explore whether they are associated with incidence of bone metastasis development.
Material and Methods
DNA EXTRACTION AND SNP GENOTYPING ANALYSIS:
Genomic DNA was prepared using the QIAamp DNA mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. DNA samples were stored at −20°C until genotypic analysis was performed. SNP rs13347 and rs187115 in CD44 gene were genotyped using the Taqman allelic discrimination method (Applied Biosystems, Foster City, CA, USA) [39]. The PRIMER sequences were previously described [36]. The TaqMan assays were conducted in a final reaction volume of 5 ml containing 0.25 ml primer, 0.125 ml probe, 2 ml PCR mixture reagent, and 25 ng DNA. The polymerase chain reaction (PCR) consisted of an initial step at 95°C for 10 min followed by 55 cycles of denaturing at 95°C for 15 s and annealing at 60°C for 1 min [36,40]. Allelic discrimination software was used to analyze the PCR genotyping results.
STATISTICAL ANALYSIS:
All statistical analyses were performed using SPSS19.0 software (SPSS Company, Chicago, IL). Hardy-Weinberg equilibrium (HWE) was evaluated using a χ2-test. The differences in distributions of the variables between patients and healthy controls were evaluated by Mann-Whitney U test and Fisher’s exact test. The comparison of allele type and genotype distributions in the patients and healthy controls was assessed by computing the odds ratio (OR) and 95% confidence intervals (95% CI) from logistic regression analyses. Survival was calculated from the date of surgery to the time of death using the Kaplan-Meier method.
Results
PATIENT CLINICAL CHARACTERISTICS:
Among a total of 702 subjects of this study, the mean age was 62.21±9.8 years in cases and 61.87±10.75 in matched-pair controls. There were no significant differences in mean age and sex distributions between cases and controls. Distribution of genotypes of the 2 polymorphisms in healthy control group was in accordance with Hardy-Weinberg equilibrium in our study. Of the 234 NSCLC patients, 65 (28%) were diagnosed with bone metastasis. The follow-up period ranged from 23 to 117 months (median, 60 months; mean, 71 months). Among the 234 patients, 171 patients survived less than 5 years and 63 patients survived over 5 years (5-year survival rate of 27%). Characteristics of NSCLC patients and age- and sex-matched controls are shown in Table 1.
CD44 GENE POLYMORPHISMS WITH NSCLC:
Table 2 shows the association of each of the SNPs in CD44 gene with the risk of NSCLC. There were no significant differences in the genotypic and allelic distributions of rs13347 polymorphisms between NSCLC patients and healthy controls. However, significant differences were observed in the relationship between frequency distributions of rs187115 and the NSCLC risk. Allele G of rs187115 SNP significantly increased NSCLC risk.
As shown in Table 3, further analysis based on stratification of clinicopathological features revealed significant correlations of frequency distributions of rs187115 SNP with NSCLC risk in tumor stage (OR=2.6, 95%CI: 1.50–4.45, P=0.001) and bone metastasis (OR=0.4, 95%CI: 0.20–0.64, P<0.001). By comparing with AA genotype, the results indicated that genotype of AG plus GG at rs187115 might significantly increase presence of advanced stage and the risk of development of bone metastasis.
CD44 GENE POLYMORPHISMS WITH NSCLC PROGNOSIS:
Patient survival analysis showed a clear positive correlation between different genotypes at rs187115 in CD44 gene (P<0.001, log-rank=25.999) (Figure 1). The survival rates for patients with the AA genotype were significantly higher than for patients with the AG+GG genotypes (P<0.001). Then, we carried out Cox regression analysis. After the univariate analysis, we found that the genotype of rs187115 and 2 clinicopathological parameters – tumor stage and bone metastasis – might be associated with the prognosis of NSCLC (Table 4). Further analyses of all variables in multivariate analysis subsequently revealed that CD44 gene (AG+GG) (RR=0.48, 95%CI: 0.34–0.68, P<0.001), tumor stage (RR=0.45, 95%CI: 0. 0.31–0.65, P<0.001), and bone metastasis (RR=1.52, 95%CI: 1.05–2.21, P=0.027) might also be independent prognostic factors for NSCLC (Table 4).
Discussion
In the present study, we showed the effects of CD44 on prognosis of NSCLC and the risk of development of bone metastasis. To the best of our knowledge, this is the first investigation to report an association between CD44 polymorphisms and bone metastasis among NSCLC patients. The results in this study revealed that CD44 gene rs187115 polymorphism is a potential predictive marker of survival in NSCLC patients, and is significantly associated with bone metastasis and tumor stage.
NSCLC is a common tumor with poor prognosis. Many studies [12,41,42] have investigated the role of genetic factors in the progression and prognosis of NSCLC. A large body of evidence [25–28] suggests that CD44 gene participates in the regulation of tumor metastasis and that overexpression of CD44 is particularly observed in metastatic tumors, especially in those cancers that have a high propensity for the development of bone metastases [37,43,44]. Moreover, the overexpression of CD44 in the primary tumor is reportedly associated with early metastasis and poor prognosis in human cancers [26,37,43–45].
It has been reported that CD44 is a cofactor with tumor promotion and tumor suppression [46,47]. It can enhance the affinity of growth factors to their authentic receptors; therefore, CD44 might play roles in proliferation and invasiveness of cells. In contrast, in other situations CD44 acts as tumor suppressor by binding to alternative ligands, resulting in growth arrest due to contact inhibition [43]. The roles of CD44 in a given cell will depend on the subtype of CD44, cellular nature of the ECM, and other unknown conditions [46].
In the current study, we found that the distribution of genotype in the CD44 gene showed significant differences between patients with and without bone metastasis, but we found no significant difference between positive and negative lymph node metastasis (Table 3). A study by Ramasami et al. [48] also showed CD44 had no significant association with lymph node metastases or tumor stage. However, Ko et al. [22] found a strong association between CD44 gene and advanced lymph node metastasis. CD44 has unconfirmed roles in metastases in patients with tumors, and further study is needed to investigate this.
Previous studies have reported varied relationships of CD44 in cancer susceptibility and prognosis. Vazquez et al. [49] reported that allele G of CD44 (rs187115) was associated with increased risk for tumor-related death and lower drug sensitivity. Jiang et al. [50] CD44rs13347 C>T found that polymorphism may affect breast cancer development and prognosis by increasing CD44 expression. Xiao et al. [44] also found that CT and TT genotypes of rs13347 in CD44 gene were associated with increased risk of nasopharyngeal carcinoma. However, Tulsyan et al. [37] did not observe any significant differences in the frequency distribution of the genetic variants CD44 rs13347 between cases and healthy controls. In our study, we found that rs187115 was associated with NSCLC; however, the relationship between rs13347 and NSCLC was not observed. Allelic G carrier has an increased risk of NSCLC and achieves a poor prognosis. Moreover, rs187115 polymorphism is significantly correlated with bone metastasis and tumor stage. SNP rs187115 might become a potential prognostic marker for NSCLC patients.
Some limitations in this study design must be noted. First, selection bias may have occurred because the cases were enrolled from hospital but the healthy controls were chosen from the community. Second, the small sample size may cause significant fluctuations in statistics. Finally, replication in another group was not carried out.
Conclusions
In summary, our study indicated that CD44 rs187115 variant genotypes (AG + GG) could increase the risk of NSCLC and decrease survival time compared with AA genotype, and rs187115 was correlated with bone metastasis and tumor stage. However, well-designed, population-based, case-control studies with lager sample sizes are required to confirm these results.
References
1. Ferlay J, Shin HR, Bray F, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008: Int J Cancer, 2010; 127(12); 2893-917, pmid: 21351269
2. Bi N, Yang M, Zhang L, Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer: Clin Cancer Res, 2010; 16(8); 2383-90, pmid: 20332326
3. Gandara D, Narayan S, Lara PN, Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer: Clin Cancer Res, 2005; 11(13 Pt 2); 5057s-62s, pmid: 16000614
4. Siegel R, Naishadham D, Jemal A, Cancer statistics, 2013: Cancer J Clin, 2013; 63(1); 11-30
5. Hashisako M, Wakamatsu K, Ikegame S, Flare phenomenon following gefitinib treatment of lung adenocarcinoma with bone metastasis: Tohoku J Exp Med, 2012; 228(2); 163-68, pmid: 23036980
6. Coleman RE, Clinical features of metastatic bone disease and risk of skeletal morbidity: Clin Cancer Res, 2006; 12(20 Pt 2); 6243s-49s, pmid: 17062708
7. Decroisette C, Monnet I, Berard H, Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601): J Thorac Oncol, 2011; 6(3); 576-82, pmid: 21270669
8. Tsuya A, Kurata T, Tamura K, Fukuoka M, Skeletal metastases in non-small cell lung cancer: a retrospective study: Lung Cancer, 2007; 57(2); 229-32, pmid: 17451841
9. Kozlow W, Guise TA, Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy: J Mammary Gland Biol Neoplasia, 2005; 10(2); 169-80, pmid: 16025223
10. Di Maio M, Gridelli C, Gallo C, Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer: Br J Cancer, 2004; 90(12); 2288-96, pmid: 15162156
11. Cetin K, Christiansen CF, Jacobsen JB, Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study: Lung Cancer, 2014; 86(2); 247-54, pmid: 25240518
12. Liu L, Chen X, Wang Y, Notch3 is important for TGF-beta-induced epithelial-mesenchymal transition in non-small cell lung cancer bone metastasis by regulating ZEB-1: Cancer Gene Ther, 2014; 21(9); 364-72, pmid: 25080992
13. Pockett RD, Castellano D, McEwan P, The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain: Eur J Cancer Care (Engl), 2010; 19(6); 755-60, pmid: 19708928
14. Chen Y, Liu H, Wu W, Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis: J Exp Clin Cancer Res, 2013; 32; 45, pmid: 23883434
15. Rafrafi A, Kaabachi S, Kaabachi W, CCR2-64I polymorphism is associated with non-small cell lung cancer in Tunisian patients: Hum Immunol, 2015; 76(5); 348-54, pmid: 25797207
16. Bhat IA, Naykoo NA, Qasim I, Association of interleukin 1 beta (IL-1beta) polymorphism with mRNA expression and risk of non small cell lung cancer: Meta Gene, 2014; 2; 123-33, pmid: 25606396
17. Geredeli C, Artac M, Yildirim S, Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer: Tumour Biol, 2015 [Epub ahead of print]
18. Goodfellow PN, Banting G, Wiles MV, The gene, MIC4, which controls expression of the antigen defined by monoclonal antibody F10.44.2, is on human chromosome 11: Eur J Immunol, 1982; 12(8); 659-63, pmid: 7140811
19. Bourguignon LY, Zhu D, Zhu H, CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression: Front Biosci, 1998; 3; d637-49, pmid: 9634539
20. Rafi A, Nagarkatti M, Nagarkatti PS, Hyaluronate-CD44 interactions can induce murine B-cell activation: Blood, 1997; 89(8); 2901-8, pmid: 9108410
21. Chen D, McKallip RJ, Zeytun A, CD44-deficient mice exhibit enhanced hepatitis after concanavalin A injection: evidence for involvement of CD44 in activation-induced cell death: J Immunol, 2001; 166(10); 5889-97, pmid: 11342603
22. Ko YH, Won HS, Jeon EK, Prognostic significance of CD44s expression in resected non-small cell lung cancer: BMC Cancer, 2011; 11; 340, pmid: 21819617
23. Arch R, Wirth K, Hofmann M, Participation in normal immune responses of a metastasis-inducing splice variant of CD44: Science, 1992; 257(5070); 682-85, pmid: 1496383
24. Marhaba R, Zoller M, CD44 in cancer progression: adhesion, migration and growth regulation: J Mol Histol, 2004; 35(3); 211-31, pmid: 15339042
25. Hill A, McFarlane S, Johnston PG, Waugh DJ, The emerging role of CD44 in regulating skeletal micrometastasis: Cancer Lett, 2006; 237(1); 1-9, pmid: 15979783
26. Luo Z, Wu RR, Lv L, Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review: Int J Clin Exp Pathol, 2014; 7(7); 3632-46, pmid: 25120740
27. Brown RL, Reinke LM, Damerow MS, CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression: J Clin Invest, 2011; 121(3); 1064-74, pmid: 21393860
28. Clarke MR, Landreneau RJ, Resnick NM, Prognostic significance of CD44 expression in adenocarcinoma of the lung: Clin Mol Pathol, 1995; 48(4); M200-4, pmid: 16696007
29. Bertaux-Skeirik N, Feng R, Schumacher MA, CD44 plays a functional role in Helicobacter pylori-induced epithelial cell proliferation: PLoS Pathog, 2015; 11(2); e1004663, pmid: 25658601
30. Dong C, Ye DX, Zhang WB, Pan HY, Overexpression of c-fos promotes cell invasion and migration via CD44 pathway in oral squamous cell carcinoma: J Oral Pathol Med, 2015; 44(5); 353-60, pmid: 25482572
31. Zhao S, He JL, Qiu ZX, Prognostic value of CD44 variant exon 6 expression in non-small cell lung cancer: a meta-analysis: Asian Pac J Cancer Prev, 2014; 15(16); 6761-66, pmid: 25169522
32. Quan YH, Kim B, Park JH, Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44: Exp Lung Res, 2014; 40(10); 475-84, pmid: 25299431
33. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM, Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer: Cancer Res, 2007; 67(20); 9609-12, pmid: 17942888
34. Morley M, Molony CM, Weber TM, Genetic analysis of genome-wide variation in human gene expression: Nature, 2004; 430(7001); 743-47, pmid: 15269782
35. Chou YE, Hsieh MJ, Chiou HL, CD44 gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathologic features: Biomed Res Int, 2014; 2014; 231474, pmid: 24971320
36. Chou YE, Hsieh MJ, Hsin CH, CD44 gene polymorphisms and environmental factors on oral cancer susceptibility in Taiwan: PLoS One, 2014; 9(4); e93692, pmid: 24699672
37. Tulsyan S, Agarwal G, Lal P, CD44 gene polymorphisms in breast cancer risk and prognosis: a study in North Indian population: PLoS One, 2013; 8(8); e71073, pmid: 23940692
38. Ahuja V, Coleman RE, Herndon J, Patz EF, The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma: Cancer, 1998; 83(5); 918-24, pmid: 9731895
39. Livak KJ, Allelic discrimination using fluorogenic probes and the 5′ nuclease assay: Genet Anal, 1999; 14(5–6); 143-49, pmid: 10084106
40. Huang SM, Cheung CW, Chang CS, Phloroglucinol derivative MCPP induces cell apoptosis in human colon cancer: J Cell Biochem, 2011; 112(2); 643-52, pmid: 21268086
41. Song Z, Zhang Y, Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases: Med Oncol, 2014; 31(4); 898, pmid: 24573639
42. Deberne M, Ropert S, Billemont B, Inaugural bone metastases in non-small cell lung cancer: a specific prognostic entity?: BMC Cancer, 2014; 14; 416, pmid: 24913188
43. Sharma KL, Yadav A, Gupta A, Association of genetic variants of cancer stem cell gene CD44 haplotypes with gallbladder cancer susceptibility in North Indian population: Tumour Biol, 2014; 35(3); 2583-89, pmid: 24186075
44. Xiao M, Hu S, Zhang L, Polymorphisms of CD44 gene and nasopharyngeal carcinoma susceptibility in a Chinese population: Mutagenesis, 2013; 28(5); 577-82, pmid: 23883608
45. Taira N, Kawabata T, Ichi T, Long-term survival after surgical treatment of metachronous bilateral adrenal metastases of non-small cell lung carcinoma: Am J Case Rep, 2014; 15; 444-46, pmid: 25317919
46. Herrlich P, Morrison H, Sleeman J, CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor: Ann NY Acad Sci, 2000; 910; 106-18, pmid: 10911909
47. Kanaji N, Tadokoro A, Watanabe N, Increases in serum CYFRA21-1 concentration during successful treatment with crizotinib: Am J Case Rep, 2014; 15; 480-84, pmid: 25380070
48. Ramasami S, Kerr KM, Chapman AD, Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma: J Pathol, 2000; 192(4); 427-32, pmid: 11113858
49. Vazquez A, Grochola LF, Bond EE, Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival: Cancer Res, 2010; 70(1); 172-80, pmid: 19996285
50. Jiang L, Deng J, Zhu X, CD44 rs13347 C>T polymorphism predicts breast cancer risk and prognosis in Chinese populations: Breast Cancer Res, 2012; 14(4); R105, pmid: 22788972
In Press
Clinical Research
Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...Med Sci Monit In Press; DOI: 10.12659/MSM.951027
Clinical Research
Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...Med Sci Monit In Press; DOI: 10.12659/MSM.950516
Review article
Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.951283
Clinical Research
Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 AdultsMed Sci Monit In Press; DOI: 10.12659/MSM.950938
Most Viewed Current Articles
17 Jan 2024 : Review article 10,187,196
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,708,487
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,341,643
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 706,524
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387